Join to view full profile
11 W Bridlewood DrNew Hope, PA 18938
Phone+1 215-850-6895
Fax+1 215-862-3282
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 2 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Scott Reines, MD is a board certified psychiatrist in New Hope, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Psychiatry, 1976 - 1979
Albert Einstein College of MedicineClass of 1976
Certifications & Licensure
PA State Medical License 1979 - 2026
American Board of Psychiatry and Neurology Psychiatry
Publications & Presentations
PubMed
- 17 citationsIntravenous Tramadol is Effective in the Management of Postoperative Pain Following Abdominoplasty: A Three-Arm Randomized Placebo- and Active-Controlled TrialHarold S. Minkowitz, Hernan Salazar, David A. Leiman, Daneshvari Solanki, Lucy Lu
Drugs in R&D. 2020-09-01 - 8 citationsEfficacy and Safety of Intravenously Administered Tramadol in Patients with Moderate to Severe Pain Following Bunionectomy: A Randomized, Double-Blind, Placebo-Control...Neil K. Singla, Richard Pollak, Ira J. Gottlieb, David Leiman, Harold S. Minkowitz
Pain and Therapy. 2020-07-18 - 3 citationsIV tramadol: A novel option for US patients with acute pain-A review of its pharmacokinetics, abuse potential and clinical safety recordLucy Lu, Mark Harnett, Scott A Reines
Journal of Opioid Management. 2020-07-01
Press Mentions
Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative PainMay 21st, 2018
Memory Drug Enters Clinical Trial, May Help Treat Cognitive DisordersDecember 30th, 2015
Grant Support
- MEB-1170: A New Chemical Entity for the Treatment of Opioid Use DisorderMEBIAS DISCOVERY, INC.2025–2027
